Novartis Ag

Sandoz Gmbh

David Bodmer

Thomas Kissel

Oskar Nagele

Rainer Albert

Bernhard Wietfeld

Wilfried Bauer

Mark Meisenbach

Ian Lewis

Heribert Hellstern

Gisbert Weckbecker

Hawkins V Maulding

Christian Bruns

Jones W Fong

Ivo Felner

Jane E Pearson

Murat Acemoglu

Peter C Hiestand

Salvatore Cammisuli

Siegfried Bantle

Fritz Nimmerfall

Georg Stoll

Friedrich Richter

Michael Ausborn

Harry Tiemessen

Laurent Marchal

The invention provides cyclo[{4-(NH&#x2014;CH&#x2014;NH&#x2014;CO&#x2014;O&#x2014;)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Somatostatin analogues

The invention provides cyclo[{4-(NH&#x2014;CH&#x2014;NH&#x2014;CO&#x2014;O-)Pro}-Phg-DTrp-Lys-Tyr(4-Benzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.

Allylamine-containing liposomes

This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF&agr;, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.

Polymeric matrices and their uses in pharmaceutical compositions

An emulsion-based method of microencapsulating an active agent wherein a water-in-oil emulsion, containing a matrix-forming polymer and an active agent, is dispersed in an aqueous external phase to form a microencapsulated product.

Organic compounds

This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF.alpha., e.g., certain autoimmune and inflammatory conditions, as well as septic shock.

The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Sustained release formulations of water soluble peptides

The invention discloses microparticles comprising a polypeptide, preferably somatostatin or an analog or derivative thereof, more preferably octreotide, in a polymeric matrix, preferably poly(lactide-co-glycolide)glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating acromegaly and breast cancer.

Growing community of inventors

Klingnau, Switzerland

David Bodmer